phosphamide (Cytoxan) was injected, seemed promising in preventing hair loss (1, 2) . The few brief evaluations of scalp tourniquet effectiveness in the literature since then, however, have been highly impressionistic and contradictory (3, 4, 5, 6) . Either no controlled studies had been undertaken, or they had not been reported because of the negative results.
Two main issues were involved in planning a study of scalp tourniquet use: the viability of the rationale for the scalp tourniquet use and the feasibility of testing it, given the contingencies of modern treatment procedures.
The rationale for using a scalp Circulation To The Scalp superficial temporal artery occipital artery postenrior auricular artery facial artery external carotid artery tourniquet is that drug contact with hair follicles can be minimized because the scalp is supplied by superficial blood vessels, which can be temporarily occluded by pressure, and because the drugs are rapidly cleared from the blood after injection, presumably because of tissue fixation (7) . Theoretically, then, it was necessary to look at the nature of normal hair growth, the effects of cancer chemotherapy on scalp hair, the scalp blood supply, and the pharmacokinetics of the drugs to evaluate the hypothesis that a scalp tourniquet could prevent hair loss.
How Hair Grows
Each hair grows at a steady rate, independently from all the others (8) . Each follicle has a bul- At intervals, mitosis stops suddenly, and the hair root undergoes involution and enters a period of dormancy. The old hair is then shed, and a new one begins to grow.
Thus, hair growth occurs in three phases: anagen, the phase of active growth, which lasts for approximately three years in the scalp and involves 90 percent of the hair at a time; telogen, the dormant phase, lasting three months and involving 10 percent of hairs; and catagen, or involution, lasting only a day and involving less than one percent of hairs. Hairs on other parts of the body have a much shorter period of anagen, appropriate to their length. For instance, hairs on the arm are in the anagen phase for only three months at a time.
Regardless of its site of action or the mechanism of action, each epilating drug interferes with hair growth by blocking at one step or another the mitotic cycle of the matrix cells in the bulb (9, 10 Drugs given by intravenous bolus injections achieve immediate peak plasma levels and then taper off. In this instance, the scalp tourniquet would seem to be more effective when applied just before injection and left on 20 minutes. If the drug is given by infusion, hair follicle protection is more difficult to achieve. It is not possible to leave the scalp tourniquet in place for more than 20 minutes, as it will become too uncomfortable for the patient. Although the patient experiences no dizziness, syncope, or headache, the head feels tightly "squeezed," and the scalp soon becomes numb. Since peak plasma levels are more slowly The sample was drawn from patients at the Veterans Administration Medical Center, Portland, Oregon, who were about to be treated with chemotherapy for advanced bronchogenic carcinoma.
The study was planned originally to include randomization to five possible different chemotherapeutic treatments, a national study with four arms and one local study. The participation of 40 to 50 patients was anticipated. Just after the study began, however, the national study was changed. Only the local portion of the design, called COCA, Hair loss following methotrexate therapy is associated with the administration of large amounts of the drug and generally occurs with such other forms of clinical toxicity as stomatitis, leukopenia, and
